At present, the treatment of T2DM with NAFLD in modern medicine is mainly based on strict control of blood glucose and diet, giving Metformin, Nitrotyrosine, α-glucosidase inhibitors, Glucagon-like peptide 1 receptor (GLP-1) agonists, Dipeptidyl peptidase 4 (DPP-4) inhibitors, Peroxisome proliferator-activated receptor (PPAR-γ/α/δ) agonist.[17–20] The mechanisms of these drugs are primarily used to improve IR. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.